Olema Oncology to Present at Upcoming Investor Conferences in November
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company will present at the following investor conferences in November:
- Presentation at the Credit Suisse 31st Annual Healthcare Conference at the Terranea Resort in Rancho Palos Verdes, CA, on Wednesday, November 9, at 9:10 a.m. Pacific Time (12:10 p.m. Eastern Time)
- Fireside chat at the Jefferies London Healthcare Conference at The Waldorf Hilton in London, UK, on Wednesday, November 16, at 11:30 a.m. GMT (6:30 a.m. Eastern Time)
- Virtual fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, at 2:40 p.m. Eastern Time
Live webcasts of the presentations and any accompanying presentation materials will be available under the Investors & Media section of Olema’s website () and will be archived for at least 30 days.
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers. Olema’s lead product candidate, OP-1250, is a proprietary, orally-available small molecule with dual activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated both as a single agent in an ongoing Phase 2 clinical trial, and in combination with CDK 4/6 inhibitors (palbociclib and ribociclib) and a PI3Ka inhibitor (alpelisib), in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. OP-1250 has been granted FDA Fast Track designation. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
IR Contact:
Shane Kovacs, COO and CFO
Media Contact:
Ignacio Guerrero-Ros, Ph.D., Russo Partners
646-942-5604
